NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Simple Peptide

Published 12 Nov 2026. 38-page investigative report on who is behind Simple Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Simple Peptide is not a one-storefront case. The canonical site points to Melex Technologies Inc., but the record branches into a manager-level family holding vehicle, sister RUO brands, wholesale and white-label channels, live or pre-launch telehealth brands, API pages, and exosome sales. The practical buyer question is narrower than ownership gossip: which entity is selling, filling, testing, releasing, and standing behind the vial you receive.

Across 53 Finnrick lab tests, Simple Peptide posts a 57% overall pass rate: 30 pass and 23 fail. The record is uneven rather than uniformly bad. GHK-Cu and the tested Tirzepatide record are the clearest stronger signals, Retatrutide is the mixed middle, and CJC-1295 is the sharpest caution flag; ratings also narrow under stricter grading, so the full product-by-methodology view matters.

The non-testing findings are the real hook. simplepeptide.com says it is the only official site, while a brand-identical .is storefront claims official status and carries GLP-1-like products absent from the .com sitemap. Ascellos is positioned for injectable/nebulizer use while the public evidence does not supply the sterility, source, handling, or regulatory support a buyer would need; meanwhile, U.S. cGMP and compounding language remains facility-unspecific.

Simple Peptide has positives: lot-level COAs, a lab lookup path, live U.S. support, and an operating history longer than disposable peptide shops. But the COA story has a caveat: Freedom Diagnostics claims no conflicts while Simple Peptide describes itself as the lab's first and largest customer. Public sources reviewed also did not identify who has technical authority over sourcing, QA, or batch release; that is a disclosure limitation, not proof that competent oversight is absent.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 9 tested products
  • Melex / Simple Family LLLP entity and channel map covering RUO, wholesale, API, cosmetics, and telehealth brands
  • simplepeptide.com versus simplepeptides.is catalog and official-site conflict analysis
  • Ascellos exosome evidence review, including injectable/nebulizer positioning and missing public support
  • Freedom Diagnostics COA lookup, lot movement, and lab-independence analysis
  • Trademark, litigation, affiliate/MLM, and XRay Payment rail findings

Risk assessment

  • Product-quality risk for weak tested SKUs — high: BPC-157 at 48.12%, Tesamorelin at 47.98%, CJC-1295 at 25.99%, and Melanotan II at 53.77% with 0/3 passes are materially weaker than GHK-Cu and Tirzepatide.
  • Ascellos exosome product risk — high: Ascellos is described for injectable/nebulizer use, has no research information on the Simple Peptide page, and Simple Life Science lists it as not research-use-only with guest checkout.
  • Official-channel and brand-confusion risk — high: simplepeptide.com says it is the only official site while simplepeptides.is claims official status and lists GLP-1-like products; authorization is unresolved.
  • Corporate and contracting-transparency risk — high: Melex, The Simple Family LLLP, SPW International and dissolved PeptiMed/SimpleProRx LLC records leave live-site seller and fulfiller identity unclear.
  • Manufacturing and facility-verification risk — high: Public pages claim U.S. cGMP/compounded production but do not disclose the facility, registration, pharmacy status or release authority, and terms say the group does not compound drugs.
  • Clinical/compounded-channel transparency risk — medium: MySimpleMed and Simple Pro Rx route care through Stealth Health while Melex filings cover telehealth/pharmacy/compounded peptides; provider, pharmacy and entity disclosures require verification.
  • Lab-independence and COA-reliance risk — medium: Freedom Diagnostics COAs are useful but Freedom claims no conflicts while Simple Peptide says it was the lab’s first and largest customer.
  • Affiliate-promotion and reputation-management risk — medium: Prior affiliate scan found 15 promoter leads, 13 with code/link and 8 without clear disclosure; Trustpilot removed the profile and review-conditioned refund allegations remain unresolved.
  • Litigation and legal-process risk — medium: Open Melex v. Baum trade-secret case, Ehrenthal v. Baum dissolution matter and Robertson docket exist with no merits disposition in supplied records.